Oruka Therapeutics (ORKA)
Develops extended-half-life antibodies for psoriasis, hidradenitis suppurativa and related inflammatory diseases.
Something off on this page? Send us feedback.
Develops extended-half-life antibodies for psoriasis and related inflammatory diseases, led by IL-23p19 candidate ORKA-001 and IL-17A/F candidate ORKA-002. With no approved products, the business depends on clinical development, Paragon-licensed rights, outsourced manufacturing and regulatory approval.
Develops extended-half-life monoclonal antibodies for psoriasis and other inflammatory diseases. ORKA-001 targets IL-23p19 and is in mid-stage studies for moderate-to-severe plaque psoriasis. ORKA-002 blocks IL-17A and IL-17F and is being studied in plaque psoriasis and hidradenitis suppurativa.
Applies antibody engineering to validated immune pathways, prioritizing deep disease clearance and less frequent dosing. The planned ORKA-021 regimen sequences ORKA-002 induction with ORKA-001 maintenance, while ORKA-004 adds a half-life-extended TL1A antibody intended for combination development.
Operations are US-based, while clinical work includes the United States and Canada and worldwide rights cover the lead programs. No candidate is approved, and the business depends on Paragon-licensed intellectual property, third-party manufacturing, successful trials and regulatory review.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 1, 2026 | UBS | Reiterate | Buy | $100 | $130 |
| Jun 2, 2026 | Piper Sandler | Target | $75 | $180 | |
| Apr 30, 2026 | Leerink Partners | Target | $120 | ||
| Apr 29, 2026 | H.C. Wainwright | Target | $40 | $120 | |
| Apr 28, 2026 | UBS | Reiterate | Buy | $50 | $100 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $873.6M · Total debt $2.5M · Total assets $1.14B · Shareholders' equity $1.11B
- Revenue
- $0
- Operating income
- −$50.1M
- Net income
- −$41.2M
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 29, 2024 | Aug 26 | $1.613 | special dividend |
| Institutions266 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 121.11% | 73.04M shares | |
| Insiders8 holders · as of Sep 1, 2026 | 2.43% | 1.47M shares | |
| Adds to | 123.54% |
60.31M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 123.54%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 15.02% | 9.06M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.27% | 4.99M | 13Fas of Jun 30, 2026 |
VR Adviser, LLCInstitution | 6.88% | 4.15M | 13Fas of Jun 30, 2026 |
Fairmount Funds Management LLCInstitution | 6.14% | 3.71M | 13Fas of Jun 30, 2026 |
Capital World InvestorsInstitution | 5.64% | 3.40M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Lawrence Otto Klein | director, officer: Chief Executive Officer | −75,000 | $91.83 |
| Sep 1, 2026 | Laura Lee Sandler | officer: Chief Operating Officer | −5,000 | $91.82 |
| Aug 17, 2026 | Joana Goncalves | officer: Chief Medical Officer | −7,000 | $111.84 |
| Aug 14, 2026 | Paul T. Quinlan | officer: General Counsel | −52,000 | $108.49 |
| Aug 13, 2026 | Arjun Agarwal | officer: Senior Vice President, Finance | −10,000 | $106.66 |
- AbbVie
IL-23p19 benchmark through Skyrizi in plaque psoriasis
- Johnson & Johnson
IL-23 and IL-12/23 incumbent via Tremfya and Stelara
- Novartis (ADR)
IL-17A psoriasis incumbent through Cosentyx
- Eli Lilly
IL-17A psoriasis biologic competitor through Taltz
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oruka Therapeutics | $91.70 | −0.02% | $5.53B | — | — | — | — |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Johnson & Johnson | $274.78 | −0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Median | 35.4 | 20.2 | 7.0 | +8.4% |